SCHEDULE 13G/A: ARK Investment Management Reports Complete Divestment from Verve Therapeutics, Inc.

Sentiment:

Beneficial Ownership Disclosure 11 January 2025 2:24 AM

📋All filings for Verve Therapeutics, INC

ARK Investment Management LLC has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in Verve Therapeutics, Inc. as of September 30, 2024.

Worse than expectedARK Investment Management LLC has reduced its beneficial ownership in Verve Therapeutics, Inc. to 0 shares, representing 0.0% of the class, indicating a complete divestment from the company.

Summary

ARK Investment Management LLC, an investment adviser, has filed an Amendment No. 2 to Schedule 13G concerning its beneficial ownership in Verve Therapeutics, Inc.
As of September 30, 2024, ARK Investment Management LLC reported 0 shares beneficially owned in Verve Therapeutics, Inc.
This represents 0.0% of the common stock class of Verve Therapeutics, Inc.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 3

Explanation: The complete divestment by a prominent investment firm like ARK Investment Management LLC could be perceived negatively by the market, suggesting a lack of confidence or a strategic shift away from Verve Therapeutics.

Future Outlook

Management Comments

Kellen Carter, Chief Compliance Officer of ARK Investment Management LLC, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment adviser. The complete divestment by ARK Investment Management LLC from Verve Therapeutics, Inc. indicates a portfolio rebalancing or a change in investment thesis by the fund regarding the biotechnology sector or Verve Therapeutics specifically.

Stakeholder Impact

Shareholders: Existing and potential shareholders may interpret ARK's complete divestment as a negative signal, potentially influencing the company's stock price.

Key Dates

Date	Description
09/30/2024	Date of event which required the filing of this statement (change in beneficial ownership).
01/10/2025	Date the Schedule 13G Amendment No. 2 was signed by ARK Investment Management LLC.

Recommendation

sell

Keywords

Verve Therapeutics, ARK Investment Management, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Adviser, Divestment

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.